Standard of Care Durvalumab for Limited-Stage SCLC
Key Takeaways
- Durvalumab demonstrated promising results in limited-stage SCLC in the ADRIATIC trial, potentially improving patient outcomes.
- The ADRIATIC trial's design evaluated durvalumab's efficacy, suggesting its integration into treatment algorithms if approved.
Panelists discuss how the ADRIATIC trial investigating durvalumab in limited-stage small cell lung cancer (SCLC) has shown promising results, potentially addressing unmet needs in this patient population, and consider its potential impact on treatment algorithms and its possible emergence as a new standard of care if approved for this indication.
Now that we’ve discussed extensive-stage small cell lung cancer (SCLC), let’s move into limited stage. Durvalumab has also demonstrated encouraging results in patients with limited-stage SCLC in the
How do you see durvalumab fitting into treatment algorithms if approved? Do you see it as a potential new standard of care for patients with limited-stage SCLC?
What are the unmet needs that the ADRIATIC trial addresses for patients with limited-stage SCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
